New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3397-3401

  Feytens, Debby ^a   Cescato, Renzo ^b   Reubi, Jean Claude ^b   Tourwé, Dirk ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOINDOLO[2,3 C]AZEPIN 2 ONE; AROMATIC COMPOUND; AZEPINE DERIVATIVE; DEXTRO AMINO ACID; LYSINE; PEPTIDOMINETIC AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TRYPTOPHAN; UNCLASSIFIED DRUG; CYCLIC AMP; SOMATOSTATIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CHO CELL; CONFORMATION; CRICETULUS; HAMSTER; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; SOMATOSTATIN; TRYPTOPHAN;

EID: 34447532194     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070246f     Document Type: Article

References (37)

1. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits secretion of immunoreactive pituitary growth-hormone. Science 1973, 179, 77-79.
2. Janecka, A.; Zubrzycka, M.; Janecki, T. Somatostatin analogs. J. Pept. Res. 2001, 58, 91-107.
3. Reichlin, S. Somatostatin. 1. New Engl. J. Med. 1983, 309, 1495-1501.
4. Reichlin, S. Somatostatin. 2. New Engl. J. Med. 1983, 309, 1556-1563.
5. Hoyer, D.; Bell, G. I.; Epelbaum, J.; Fenuik, W.; Humphrey, P. P. A.; O'Carroll, A.-M.; Patel, Y. C.; Schonbrunn, A.; Taylor, J. E.; Reisine, T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 1995, 16, 86-88.
6. Melacini, G.; Zhu, Q.; Osapay, G.; Goodman, M. A refined model for the somatostatin pharmacophore: Conformational analysis of lanthionine-sandostatin analogs. J. Med. Chem. 1997, 40, 2252-2258.
7. Veber, D. F. Design and discovery in the development of peptide analogs. In Peptides, chemistry and biology, Proceedings of the 12th American Peptide Symposium, Cambridge, Massachusetts, June 16-21, 1991; Smith, J. A., Rivier, J. E., Eds.; ESCOM: Leiden, The Netherlands, 1992; pp 3-14
8. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless, J. Sms 201-995 - A very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci. 1982, 31, 1133-1140.
9. Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Paleveda, W. J.; Holly, F. W.; Strachan, R. G.; Nutt, R. F.; Arison, B. H.; Homnick, C.; Randall, W. C.; Glitzer, M. S.; Saperstein, R.; Hirschmann, R. A potent cyclic hexapeptide analog of somatostatin. Nature 1981, 292, 55-58.
10. Lamberts, S. W. J. The role of somatostatin in the regulation of anterior-pituitary hormone-secretion and the use of its analogs in the treatment of human pituitary-tumors. Endocr. Rev. 1988, 9, 417-436.
11. Chaudhry, A.; Kvols, L. Advances in the use of somatostatins in the management of endocrine tumors. Curr. Opin. Oncol. 1996, 8, 44-48.
12. Grace, C. R. R.; Erchegyi, J.; Koerber, S. C.; Reubi, J. C.; Rivier, J.; Riek, R. Novel sst(2)-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J. Med. Chem. 2006, 49, 4487-4496.
13. Pohl, E.; Heine, A.; Sheldrick, G. M.; Dauter, Z.; Wilson, K. S.; Kallen, J.; Huber, W.; Pfaffli, P. J. Structure of octreotide, a somatostatin analog. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1995, 51, 48-59.
14. Arison, B. H.; Hirschmann, R.; Veber, D. F. Inferences about the conformation of somatostatin at a biologic receptor based on NMR studies. Bioorg. Chem. 1978, 7, 447-451.
15. Giusti, M.; Ciccarelli, E.; Dallabonzana, D.; Delitala, G.; Faglia, G.; Liuzzi, A.; Gussoni, G.; Disem, G. G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur. J. Clin. Invest. 1997, 27, 277-284.
16. Liebow, C.; Reilly, C.; Serrano, M.; Schally, A. V. Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2003-2007.
17. Yang, L. H. Non-peptide somatostatin receptor ligands. Annu. Rep. Med. Chem. 1999, 34, 209-218.
18. Jones, R. M.; Boatman, P. D.; Semple, G.; Shin, Y. J.; Tamura, S. Y. Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors. Curr. Opin. Pharmacol. 2003, 3, 530-543.
19. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D.; Brans, C. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat. Rev. Drug Discovery 2003, 2, 999-1017.
20. Chianelli, D.; Kim, Y. C.; Lvovskiy, D.; Webb, T. R. Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: Synthesis of ligands for somatostatin receptors. Bioorg. Med. Chem. 2003, 11, 5059-5068.
21. Damour, D.; Barreau, M.; Blanchard, J. C.; Burgevin, M. C.; Doble, A.; Pantel, G.; Labaudiniere, R.; Mignani, S. Synthesis and binding affinities of novel spirocyclic lactam peptidomimetics of somatostatin. Chem. Lett. 1998, 943-944.
22. Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Salvino, J.; Leahy, E. M.; Sprengeler, P. A.; Furst, G.; Smith, A. B.; Strader, C. D.; Cascieri, M. A.; Candelore, M. R.; Donaldson, C.; Vale, W.; Maechler, L. Nonpeptidal peptidomimetics with a Beta-D-glucose scaffolding - A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance-P antagonist. J. Am. Chem. Soc. 1992, 114, 9217-9218.
23. Mowery, B. P.; Prasad, V.; Kenesky, C. S.; Angeles, A. R.; Taylor, L. L.; Feng, J. J.; Chen, W. L.; Lin, A.; Cheng, F. C.; Smith, A. B.; Hirschmann, R. Catechol: A minimal scaffold for non-peptide peptidomimetics of the i+1 and i+2 positions of the beta-turn of somatostatin. Org. Lett. 2006, 8, 4397-4400.
24. Papageorgiou, C.; Borer, X. A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure. Bioorg. Med. Chem. Lett. 1996, 6, 267-272.
25. Souers, A. J.; Virgilio, A. A.; Rosenquist, A.; Fenuik, W.; Ellman, J. A. Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of beta-turn mimetic libraries. J. Am. Chem. Soc. 1999, 121, 1817-1825.
26. Rohrer, S. P.; Birzin, E. T.; Mosley, R. T.; Berk, S. C.; Hutchins, S. M.; Shen, D. M.; Xiong, Y. S.; Hayes, E. C.; Parmar, R. M.; Foor, F.; Mitra, S. W.; Degrado S. J.; Shu, M.; Klopp, J. M.; Cai, S. J.; Blake, A.; Chan, W. W. S.; Pasternak, A.; Yang, L. H.; Patchett, A. A.; Smith, R. G.; Chapman, K. T.; Schaeffer, J. M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282, 737-740.
27. Yang, L. H.; Guo, L. Q.; Pasternak, A.; Mosley, R.; Rohrer, S.; Birzin, E.; Foor, F.; Cheng, K.; Schaeffer, J.; Patchett, A. A. Spiro[1H-indene- 1,4′-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst(2)) agonists. J. Med. Chem. 1998, 41, 2175-2179.
28. Yang, L. H.; Berk, S. C.; Rohrer, S. P.; Mosley, R. T.; Guo, L. Q.; Underwood, D. J.; Arison, B. H.; Birzin, E. T.; Hayes, E. C.; Mitra, S. W.; Parmar, R. M.; Cheng, K.; Wu, T. J.; Butler, B. S.; Foor, F.; Pasternak, A.; Pan, Y. P.; Silva, M.; Freidinger, R. M.; Smith, R. G.; Chapman, K.; Schaeffer, J. M.; Patchett, A. A. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10836-10841.
29. Hruby, V. J.; Li, G. G.; HaskellLuevano, C.; Shenderovich, M. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 1997, 43, 219-266.
30. Pulka, K.; Feytens, D.; Van den Eynde, I.; De Wachter, R.; Kosson, P.; Misicka, A.; Lipkowski, A.; Chung, N. N.; Schiller, P. W.; Tourwé, D. Synthesis of 4-amino-3-oxo-tetrahydroazepino[3,4-b]-indoles: New conformationally constrained Tip analogs. Tetrahedron 2007, 63, 1459-1466.
31. Sheppeck, J. E.; Kar, H.; Hong, H. A convenient and scaleable procedure for removing the Fmoc group in solution. Tetrahedron Lett. 2000, 41, 5329-5333.
32. Reubi, J. C.; Schar, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Mäcke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
33. Reubi, J. C.; Eisenwiener, K. P.; Rink, H.; Waser, B.; Mäcke, H. R. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. 2002, 456, 45-49.
34. Reubi, J. C.; Schaer, J. C.; Wenger, S.; Hoeger, C.; Erchegyi, J.; Waser, B.; Rivier, J. SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13973-13978.
35. Huang, Z. W.; He, Y. B.; Raynor, K.; Tallent, M.; Reisine, T.; Goodman, M. Main chain and side-chain chiral methylated somatostatin analogs - Syntheses and conformational analyses. J. Am. Chem. Soc. 1992, 114, 9390-9401.
36. Van Rompaey, K.; Ballet, S.; Tomboly, C.; De Wachter, R.; Vanommeslaeghe, K.; Biesemans, M.; Willem, R.; Tourwé, D. Synthesis and evaluation of the beta-turn properties of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and of their spirocyclic derivative. Eur. J. Org. Chem. 2006, 2899-2911.
37. Damour, D.; Herman, F.; Labaudiniere, R.; Pantel, G.; Vuilhorgne, M.; Mignani, S. Synthesis of novel proline and gamma-lactam derivatives as non-peptide mimics of somatostatin/sandostatin (R). Tetrahedron 1999, 55, 10135-10154.